Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Ependymoma
Inclusion Criteria
- Patients must be newly diagnosed with histologically confirmed intracranial ependymoma; patients with classic ependymoma (WHO II) or anaplastic ependymoma (WHO III) are eligible, as are various subtypes described as clear cell, papillary, cellular or a combination of the above
- There is no minimum performance level; children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor; in the majority of cases, there is neurologic recovery; neurologic recovery is not likely to be impeded by protocol therapy
- REGULATORY: All patients and/or their parents or legal guardians must sign a written informed consent
- REGULATORY: All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria
- Patients with evidence of metastatic disease will be excluded; any evidence of non-contiguous spread beyond the primary site as determined by pre or post-operative magnetic resonance (MR) imaging of brain, pre or post-operative MR imaging of the spine, and post-operative cerebrospinal fluid (CSF) cytology obtained from the lumbar CSF space (the requirement for lumbar CSF examination may be waived if deemed to be medically contraindicated); CSF cytology from a ventriculostomy or permanent ventriculoperitoneal (VP) shunt that reveals the presence of tumor cells is indicative of metastatic disease
- Patients with a diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma are NOT eligible
- No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment
- Pregnant female patients are not eligible for this study
- Post-menarchal females may not participate unless a pregnancy test with a negative result has been obtained
- Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- Lactating females may not participate unless they have agreed not to breastfeed a child while on this study
Alabama
Birmingham
Arizona
Mesa
Phoenix
Tucson
Arkansas
Little Rock
California
Downey
Duarte
Loma Linda
Long Beach
Los Angeles
Madera
Oakland
Orange
Palo Alto
Sacramento
San Diego
San Francisco
Colorado
Aurora
Connecticut
Hartford
New Haven
Delaware
Wilmington
District of Columbia
Washington
Florida
Fort Lauderdale
Fort Myers
Gainesville
Hollywood
Jacksonville
Miami
Orlando
Pensacola
Saint Petersburg
Tampa
West Palm Beach
Georgia
Atlanta
Augusta
Savannah
Hawaii
Honolulu
Idaho
Boise
Illinois
Chicago
Maywood
Oak Lawn
Peoria
Springfield
Indiana
Indianapolis
Iowa
Des Moines
Iowa City
Kentucky
Lexington
Louisville
Louisiana
New Orleans
Maine
Bangor
Scarborough
Maryland
Baltimore
Bethesda
Massachusetts
Boston
Springfield
Michigan
Ann Arbor
Detroit
East Lansing
Flint
Grand Rapids
Kalamazoo
Minnesota
Minneapolis
Rochester
Mississippi
Jackson
Missouri
Columbia
Kansas City
Saint Louis
Nebraska
Omaha
Nevada
Las Vegas
New Hampshire
Lebanon
New Jersey
Hackensack
Livingston
Morristown
New Brunswick
Newark
Paterson
Summit
New Mexico
Albuquerque
New York
Albany
Bronx
Buffalo
Mineola
New Hyde Park
New York
Rochester
Syracuse
Valhalla
North Carolina
Chapel Hill
Charlotte
Winston-Salem
North Dakota
Fargo
Ohio
Akron
Cincinnati
Cleveland
Columbus
Dayton
Toledo
Oklahoma
Oklahoma City
Oregon
Portland
Pennsylvania
Allentown
Bethlehem
Danville
Hershey
Philadelphia
Pittsburgh
Rhode Island
Providence
South Carolina
Charleston
Columbia
Greenville
South Dakota
Sioux Falls
Tennessee
Chattanooga
Knoxville
Memphis
Nashville
Texas
Austin
Corpus Christi
Dallas
Fort Worth
Houston
Lubbock
San Antonio
Temple
Utah
Salt Lake City
Vermont
Burlington
Virginia
Falls Church
Norfolk
Portsmouth
Richmond
Roanoke
Washington
Seattle
Spokane
Tacoma
West Virginia
Charleston
Morgantown
Wisconsin
Green Bay
Madison
Marshfield
Milwaukee
Alberta
Calgary
Edmonton
British Columbia
Vancouver
Manitoba
Winnipeg
Newfoundland and Labrador
Saint John's
Nova Scotia
Halifax
Ontario
Hamilton
Kingston
London
Ottawa
Toronto
Quebec
Montreal
Quebec
Saskatchewan
Saskatoon
Australia
Clayton
Herston
Hunter Regional Mail Centre
North Adelaide
Parkville
Perth
Randwick
South Brisbane
Westmead
New Zealand
Christchurch
Grafton
PRIMARY OBJECTIVE:
I. To determine the event free survival (EFS) and overall survival (OS) of children with completely resected ependymoma treated with post-operative conformal radiation therapy (cRT) and then randomized to receive or not receive four cycles of post radiation maintenance chemotherapy (vincristine, cisplatin, etoposide and cyclophosphamide [VCEC]).
EXPLORATORY OBJECTIVES:
I. To estimate the EFS and OS of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery who will then be non-randomly assigned to cRT followed by four cycles of maintenance chemotherapy (VCEC).
II. To further evaluate the EFS and OS of children with supratentorial classic ependymoma who achieve a complete resection at first or second resection OR children who achieve a CR to short course induction chemotherapy following first surgery.
III. To evaluate whether the addition of maintenance chemotherapy post-radiation therapy contributes to neurobehavioral morbidity and reduced functional outcomes over time, compared to patients treated with radiation therapy followed by observation alone.
IV. To examine differences in neurobehavioral outcomes and quality of life of children treated with proton beam radiation therapy compared to children treated with conventional radiation delivery techniques.
V. To evaluate biologic prognostic factors in childhood ependymoma by studying molecular groups as defined by deoxyribonucleic acid (DNA) methylation profiling and immunohistochemistry, copy number variants to identify 1q gain in posterior fossa ependymomas, CDKN2A loss (homozygous deletion) in supratentorial ependymomas and specific genetic alterations such as RELA fusions, YAP1 fusions and the H3 K27M mutation on initial tumor samples and correlating these data with clinical outcome.
Va. To explore prognostic molecular signatures and genomic alterations in ependymomas by building upon the data derived from ACNS0121 to correlate biomarkers listed above with World Health Organization (WHO) grade, location, extent of resection, treatment, EFS and OS.
OUTLINE: Patients are assigned to Arm I or randomized to Arms II or III.
Arm I: Patients receive vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with complete response are randomized to Arm II or III. Patients achieving stable disease, partial response, or locally progressive disease and who are deemed potentially resectable undergo surgery within 15 days after completion of induction chemotherapy. Patients with sub total resection are assigned to Arm II. Patients with gross total resection undergo observation.
ARM II: Patients undergo conformal radiotherapy over 6-7 weeks. Patients then receive vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
ARM III: Patients undergo conformal radiotherapy over 6-7 weeks and then undergo observation.
After completion of study therapy, patients are followed up every 4 months for 5 years, and then annually thereafter.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Children's Oncology Group
Principal Investigator
Amy Amundson Smith
- Primary ID ACNS0831
- Secondary IDs NCI-2011-02029, 10-01676, CDR0000668560, COG-ACNS0831
- Clinicaltrials.gov ID NCT01096368